menu
    • menu
    [{"orgOrder":0,"company":"National Healthcare Group, Singapore","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SINGAPORE","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Urokinase","moa":"Urokinase-type plasminogen activator","graph1":"Nephrology","graph2":"Phase IV","graph3":"National Healthcare Group, Singapore","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Catheter","sponsorNew":"National Healthcare Group, Singapore \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"National Healthcare Group, Singapore \/ Undisclosed"},{"orgOrder":0,"company":"Microbix Biosystems","sponsor":"Sequel Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CANADA","productType":"Enzyme","year":"2023","type":"Agreement","leadProduct":"Urokinase","moa":"Urokinase-type plasminogen activator","graph1":"Hematology","graph2":"Approved FDF","graph3":"Microbix Biosystems","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Microbix Biosystems \/ Sequel Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Microbix Biosystems \/ Sequel Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Urokinase

    Menu

    Urokinase

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            National Healthcare Group, Singapore

                            Country arrow
                            BioJapan
                            Not Confirmed

                            National Healthcare Group, Singapore

                            Country arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Urokinase

                            Therapeutic Area : Nephrology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of Standard Versus High Dose Urokinase for Dysfunctional Tunneled Dialysis Catheters in Haemodialys...

                            Details : Urokinase is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Failure, Chronic.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            January 31, 2025

                            Lead Product(s) : Urokinase

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Microbix Biosystems

                            Canada arrow
                            BioJapan
                            Not Confirmed

                            Microbix Biosystems

                            Canada arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Urokinase

                            Therapeutic Area : Hematology

                            Study Phase : Approved FDF

                            Sponsor : Sequel Pharma

                            Deal Size : $35.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Microbix Secures Funded Drug Commercialization Agreement

                            Details : The Agreement provides for Sequel to fund and undertake the necessary work to return Kinlytic (urokinase), a thrombolytic agent obtained from human neonatal kidney cells grown in tissue culture, to the U.S. for the clinical indication of venous catheter ...

                            Product Name : Kinlytic

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            May 16, 2023

                            Lead Product(s) : Urokinase

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved FDF

                            Sponsor : Sequel Pharma

                            Deal Size : $35.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth